Skip to main content
SpringerLink
Log in

Non-Acne Dermatologic Indications for Systemic Isotretinoin

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Systemic isotretinoin has been used to treat severe acne vulgaris for 20 years. However, isotretinoin also represents a potentially useful choice of drugs in many dermatologic diseases other than acne vulgaris. Diseases such as psoriasis, pityriasis rubra pilaris, condylomata accuminata, skin cancers, rosacea, hidradenitis suppurativa, granuloma annulare, lupus erythematosus and lichen planus have been shown to respond to the immunomodulatory, anti-inflammatory and antitumor activities of the drug. Isotretinoin also helps prevent skin cancers such as basal cell carcinoma or squamous cell carcinoma. A combination of systemic isotretinoin and interferon-α-2a may provide a more potent effect than isotretinoin alone in the prevention and treatment of skin cancers.

Systemic isotretinoin may be considered as an alternative drug in some dermatologic diseases unresponsive to conventional treatment modalities. However, randomized clinical trials aimed at determining the role of systemic isotretinoin therapy in dermatologic diseases other than acne vulgaris are required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II

Similar content being viewed by others

References

  1. Orfanos CE, Zouboulis CC, Almond-Roesler B, et al. Current use and future potential role of retinoids in dermatology. Drugs. 1997; 53: 358–88

    Article  PubMed  CAS  Google Scholar 

  2. Jones H, Blanc D, Cunliffe WJ. 13-cis retinoic acid and acne. Lancet. 1980 Nov 15; 2: 1048–9

    Article  PubMed  CAS  Google Scholar 

  3. Zoubolis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology. 2003; 206: 37–53

    Article  CAS  Google Scholar 

  4. Coble BI, Dahlgren C, Molin L, et al. Neutrophil function in psoriasis: effects of retinoids. Acta Derm Venereol. 1987; 67: 481–90

    PubMed  CAS  Google Scholar 

  5. Lehman PA, Henderson WR. Retinoid-induced inhibition of eosinophil LTC4 production. Prostaglandins. 1990; 39: 569–77

    PubMed  CAS  Google Scholar 

  6. Gollnick HPM, Dümmler U. Retinoids. Clin Dermatol. 1997; 15: 799–810

    Article  PubMed  CAS  Google Scholar 

  7. Zoubolis CC. Retinoids: which dermatologic indications will benefit in the near future?. Skin Pharmacol Appl Skin Physiol. 2001; 14: 303–15

    Google Scholar 

  8. Lefebvre P. Molecular basis for designing selective modulators of retinoic acid receptors transcriptional activities. Curr Drug Targets Immune Endocr Metabol Disord. 2001; 1: 153–64

    Article  PubMed  CAS  Google Scholar 

  9. Arechalde A, Samat J-H. Management of psoriasis: the position of retinoid drugs. BioDrugs. 2000; 13: 327–33

    Article  PubMed  CAS  Google Scholar 

  10. Recchia F, De Flippis S, Rossetti M, et al. Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase two study. Int J Oncol. 2002; 20: 1275–82

    PubMed  CAS  Google Scholar 

  11. Somos S, Farkas B. Immunomodulatory treatment of with low dose interferon and oral retinoic acid in lymphangioma like Kaposi sarcoma. Anticancer Res. 2000; 20: 541–5

    PubMed  CAS  Google Scholar 

  12. Holland DB, Gowland G, Cunliffe WJ. Inflammatory responses in acne patients treated with 13-cis-retinoic acid (isotretinoin). Br J Dermatol. 1984; 110: 343–5

    Article  PubMed  CAS  Google Scholar 

  13. Watson RR, Jackson JC, Alberts DS, et al. Cellular immune functions of adults treated with a daily, long term, low dose of 13-cis retinoic acid. J Leukoc Biol. 1986; 39: 567–77

    PubMed  CAS  Google Scholar 

  14. Dillehay DL, Jiang XL, Lamon EW. Differential effects of retinoids on pokeweed mitogen induced-B cell proliferation vs immunoglobulin synthesis. Int J Immunopharmacol. 1991; 13: 1043–8

    Article  PubMed  CAS  Google Scholar 

  15. Fahlman C, Jacobsen SE, Smeland EB, et al. All-trans and 9-cis retinoic acid inhibit growth of normal human and munine B cell precursors. J Immunol. 1995; 155: 58–65

    PubMed  CAS  Google Scholar 

  16. Adelman DC, Yen TY, Cumberland BG, et al. 13-cis retinoic acid enhances in vivo B lymphocyte differentiation in patients with common variable immunodeficiency. J Allergy Clin Immunol. 1991; 88: 705–12

    Article  PubMed  CAS  Google Scholar 

  17. Saxon A, Keld B, Braun J, et al. Long-term administration of 13-cis retinoic acid in common variable immunodeficiency: circulating IL-6 levels, B-cell surface molecule display, and in vitro and in vivo B-cell antibody production. Immunology. 1993; 80: 477–87

    PubMed  CAS  Google Scholar 

  18. Worm M, Krah JM, Manz RA, et al. Retinoic acid inhibits CD 40 + interleukin-4-mediated IgE production in vitro. Blood. 1998; 92: 1713–20

    PubMed  CAS  Google Scholar 

  19. Worm M, Herz U, Krah JM, et al. Effects of retinoids on in vitro and in vivo IgE production. Int Arch Allergy Immunol. 2001; 124: 233–6

    Article  PubMed  CAS  Google Scholar 

  20. Wozel G, Chang A, Zultak M, et al. The effects of topical retinoids on the leukotriene-B4-induced migration of polymorphonuclear leukocytes into human skin. Arch Dermatol Res. 1991; 283: 158–61

    Article  PubMed  CAS  Google Scholar 

  21. Piattelli A, Fioroni M, Santinelli A, et al. Bel-2 expression and apoptotic bodies in 13-cis retinoic acid (isotretinoin) topically treated oral leukoplakia: a pilot study. Oral Oncol. 1999; 35: 314–20

    Article  PubMed  CAS  Google Scholar 

  22. Moon TE, Levine N, Cartmel B, et al. Retinoids in prevention of skin cancer. Cancer Lett. 1997; 114: 203–5

    Article  PubMed  CAS  Google Scholar 

  23. DiGiovanna JJ. Posttransplantation skin cancer: scope of the problem, management, and role for systemic retinoid chemoprevention. Transplant Proc. 1998; 30: 2771–5

    Article  PubMed  CAS  Google Scholar 

  24. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition. 2000; 16: 1084–90

    Article  PubMed  CAS  Google Scholar 

  25. Lingen MW, Polverini PJ, Bouck NP. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest. 1996; 74: 476–83

    PubMed  CAS  Google Scholar 

  26. Karukonda SRK, Flynn TC, Bob EE, et al. The effects of drug on wound healing. Part II. Specific classes of drugs and their effect on healing wounds. Int J Dermatol. 2000; 39: 321–33

    Article  PubMed  CAS  Google Scholar 

  27. Weninger W, Rendl M, Mildner M, et al. Retinoids downregulate vascular endothelial growth factor/vascular permeability factor production by normal human keratinocytes. J Invest Dermatol. 1998; 111: 907–11

    Article  PubMed  CAS  Google Scholar 

  28. Pili R, Kruszewski MP, Hager BW, et al. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. 2001; 61: 1477–85

    PubMed  CAS  Google Scholar 

  29. Majewski S, Szmurlo A, Marczak M, et al. Synergistic effects of retinoids and interferon alpha on tumor-induced angiogenesis: antiangiogenic effect on HPV-harboring tumor-cell lines. Int J Cancer. 1994; 57: 81–5

    Article  PubMed  CAS  Google Scholar 

  30. Shklar G, Schwartz J. Tumor necrosis factor in experimental cancer regression with alphatocopherol, beta-carotene, canthaxantine and algae extract. Fur J Cancer Clin Oncol. 1988; 24: 839–50

    Article  CAS  Google Scholar 

  31. Schwartz JL, Shklar G. Retinoid and carotenoid angiogenesis: a possible explanation for enhanced oral carcinogenesis [abstract]. Nutr Cancer. 1997; 28: 218

    Article  Google Scholar 

  32. Vahlquist A, Rollman O. Clinical pharmacology of three generations of retinoids. Dermatologica. 1987; 1: 20–7

    Article  Google Scholar 

  33. Colburn WA, Gibson DM, Wiens RE, et al. Food increases the bioavailability of isotretinoin. J Clin Pharmacol. 1983; 23: 534–9

    PubMed  CAS  Google Scholar 

  34. Avis I, Mathias A, Unsworth EJ, et al. Analysis of small cell lung cancer growth inhibition by 13-cis-retinoic acid: importance of bioavailability. Cell Growth Differ. 1995; 6: 485–92

    PubMed  CAS  Google Scholar 

  35. Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhoea and acne. Dermatology. 1998; 196 (1): 140–7

    Article  PubMed  CAS  Google Scholar 

  36. Kerr IG, Lippman ME, Jenkins J, et al. Pharmacology of 13-cis-retinoic acid in humans. Cancer Res. 1982; 42: 2069–73

    PubMed  CAS  Google Scholar 

  37. Larsen FG, Nielsen-Kudsk F, Jakobsen P, et al. Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases. Clin Pharmacokinet. 1992; 23: 42–61

    Article  PubMed  CAS  Google Scholar 

  38. Vane FM, Bugge CJ, Rodriguez LC, et al. Human biliary metabolites of isotretinoin: identification, quantification, synthesis, and biological activity. Xenobiotica. 1990; 20: 193–207

    Article  PubMed  CAS  Google Scholar 

  39. Nulman I, Berkovitch M, Klein J, et al. Steady-state pharmacokinetics of isotretinoin and its 4-oxometabolite: implication for fetal safety. J Clin Pharmacol. 1998; 38: 926–30

    PubMed  CAS  Google Scholar 

  40. Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol. 1982; 6: 710–5

    Article  PubMed  CAS  Google Scholar 

  41. Cardamakis E, Kotoulas LG, Relakis K, et al. Comparative study of systemic interferon alfa-2A plus isotretinoin versus isotretinoin in the treatment of recurrent condyloma acuminatum in men. Urology. 1995; 45: 857–60

    Article  PubMed  CAS  Google Scholar 

  42. Tsambaos D, Georgiou S, Monastirli A, et al. Treatment of condylomata acuminata with oral isotretinoin. J Urol. 1997; 158: 1810–2

    Article  PubMed  CAS  Google Scholar 

  43. Peck GL, DiGiovanni JJ, Sarnoff DS, et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol. 1988; 19: 176–85

    Article  PubMed  CAS  Google Scholar 

  44. Tangrea JA, Adrianza E, Helsel WE, The Isotretinoin Basal Cell Carcinomas Study Group, et al. Clinical and laboratory adverse effects associated with long-term, low-dose isotretinoin: incidence and risk factors. Cancer Epidemiol Biomarkers Prev. 1993; 2 (4): 375–80

    PubMed  CAS  Google Scholar 

  45. Skeet RT, Huang J, Manola J, et al. A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893). Cancer Invest. 2003; 21: 41–6

    Article  CAS  Google Scholar 

  46. Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002; 20: 364–70

    Article  PubMed  CAS  Google Scholar 

  47. Triozzi PL, Walker MJ, Pellegrini AE, et al. Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Cancer Invest. 1996; 14: 293–8

    Article  PubMed  CAS  Google Scholar 

  48. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981; 47 (1): 207–14

    Article  PubMed  CAS  Google Scholar 

  49. Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996; 34: 1022–9

    Article  PubMed  CAS  Google Scholar 

  50. Erdogan FG, Yurtsever P, Aksoy D, et al. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998; 134: 884–5

    Article  PubMed  CAS  Google Scholar 

  51. Nikolowski J, Plewig G. Oral treatment of rosacea with 13-cis retinoic acid. Hautarzt. 1981; 32: 575–84

    PubMed  CAS  Google Scholar 

  52. Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa [abstract]. J Am Acad Dermatol. 1999; 41: 658

    Google Scholar 

  53. Honigsmann H, Wolff K. Isotretinoin-PUVA for psoriasis [letter]. Lancet. 1983; I: 236

    Article  Google Scholar 

  54. Sofen EL, Moy RL, Lowe NJ. Treatment of generalised pustular psoriasis with isotretinoin [letter]. Lancet. 1984; 7: 40

    Article  Google Scholar 

  55. Moy RL, Kingston TP, Lowe NJ. Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol. 1985; 121: 1297–301

    Article  PubMed  CAS  Google Scholar 

  56. Ansley A, Hawk JLM. Isotretinoin-PUVA in women with psoriasis. Br J Dermatol. 1997; 136: 798–9

    Article  Google Scholar 

  57. Clayton BD, Jorizzo JL, Hitchcock MK, et al. Adult pityriasis rubra pilaris: a 10-year case series. J Am Acad Dermatol. 1997; 36: 959–64

    Article  PubMed  CAS  Google Scholar 

  58. Peck GL, Yoder FW, Olsen TG, et al. Treatment of Darier’s disease, lamellar ichthyosis, pityriasis rubra pilaris, cystic acne, and basal cell carcinoma with oral 13-cis retinoic acid (isotretinoin). Dermatologica. 1978; 157 Suppl. 1: 11–2

    Article  PubMed  Google Scholar 

  59. Gilgor RS, Chiaramonti A, Goldsmith LA, et al. Evaluation of 13-cis-retinoic acid in lamellar ichthyosis, pityriasis rubra pilaris and Darier’s disease. Cutis. 1980; 25: 380–5

    PubMed  CAS  Google Scholar 

  60. Risch J, Ashton RE, Lowe N. 13-cis-retinoic acid for dyskeratinizing diseases: clinicopathologic responses. Clin Exp Dermatol. 1984; 9: 472–83

    Article  PubMed  CAS  Google Scholar 

  61. Dicken CH. Isotretinoin treatment of pityriasis rubra pilaris. J Am Acad Dermatol. 1987; 16: 297–301

    Article  PubMed  CAS  Google Scholar 

  62. Olsen EA, Kelly FF, Vollmer RT, et al. Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata. J Am Acad Dermatol. 1989; 20: 1023–30

    Article  PubMed  CAS  Google Scholar 

  63. Lambrinos P, Cardamakis E, Michopoulos J, et al. Comparative study of systemic interferon alfa-2a plus isotretinoin vs isotretinoin in the treatment of recurrent condylomata acuminata [abstract]. Gynecol Endocrinol. 1993; 17 Suppl. 1: 109

    Google Scholar 

  64. Kraemer KH, DiGiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with oral isotretinoin. N Engl J Med. 1988; 318: 1633–7

    Article  PubMed  CAS  Google Scholar 

  65. Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized double-blind controlled trial. Cancer Epidemiol Biomarkers Prev. 1997; 6: 949–56

    PubMed  CAS  Google Scholar 

  66. Greenberg ER, Baron JA, Stukel TA, et al. A clinical trial of beta-carotene to prevent basal cell and squamous cell carcinoma of the skin. N Engl J Med. 1990; 323: 789–95

    Article  PubMed  CAS  Google Scholar 

  67. Ellis CN, Kracht KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001; 45: S150–7

    Article  PubMed  CAS  Google Scholar 

  68. Sander CA, Pfeifer C, Kligman AM, et al. Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol. 1997; 36: 236–8

    Article  PubMed  CAS  Google Scholar 

  69. Majewski S, Skopinska M, Bollag W, et al. Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions [letter]. Lancet. 1994; 344: 1510–1

    Article  PubMed  CAS  Google Scholar 

  70. Skopinska M, Majewski S, Bolleg W, et al. Calcitriol and isotretinoin combined therapy for precancerous and cancerous skin lesions. J Dermatol Treat. 1997; 8: 5–10

    Article  Google Scholar 

  71. Dragnev KH, Rigas JR, Dimitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist. 2000; 5: 361–8

    Article  PubMed  CAS  Google Scholar 

  72. Tangrea JA, Edwards BK, Taylor PR, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinic trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Nall Cancer Inst. 1992; 84: 328–32

    Article  CAS  Google Scholar 

  73. Goldberg L, Hsu S, Alcalay J. Effectiveness of isotretinoin in preventing the appearance of basal cell carcinomas in basal cell nevus syndrome. J Am Acad Dermatol. 1989; 21: 144–5

    Article  PubMed  CAS  Google Scholar 

  74. Rudkin GH, Carlsen BT, Chung CY, et al. Retinoids inhibit squamous cell carcinoma growth and intercellular communication. J Surg Res. 2002; 103: 183–9

    Article  PubMed  CAS  Google Scholar 

  75. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis retinoic acid and interferon alpha-2a: effect of combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst. 1992; 84: 241–5

    Article  PubMed  CAS  Google Scholar 

  76. Eisenhauer EA, Lippman SM, Kavanagh JJ, et al. Combination 13-cis retinoic acid and interferon alpha-2a in the therapy of solid tumors. Leukemia. 1994; 8: 1622–5

    PubMed  CAS  Google Scholar 

  77. Toma S, Palumbo R, Vincenti M, et al. Efficiency of recombinant alpha-interferon 2a and 13-cis retinoic acid in the treatment of squamous cell carcinoma. Ann Oncol. 1994; 5: 463–5

    PubMed  CAS  Google Scholar 

  78. Nijsten TEC, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol. 2003; 49: 644–50

    Article  PubMed  Google Scholar 

  79. Schaber B, Mayer P, Schreiner T, et al. Anti-proliferative activity of natural interferon-alpha, isotretinoin and their combination varies in different human melanoma cell lines. Melanoma Res. 1994; 4: 319–26

    Article  PubMed  CAS  Google Scholar 

  80. Edwards L, Meyskens F, Levine N. Effect of oral isotretinoin on dysplastic nevi. J Am Acad Dermatol. 1989; 20: 257–60

    Article  PubMed  CAS  Google Scholar 

  81. Bearzatto A, Orlandi L, Silvestrini R, et al. Combined effects of interferon-alpha2a and 13-cis-retinoic acid on human melanoma cell growth and STAT protein expression. Melanoma Res. 1998; 8: 31–8

    Article  PubMed  CAS  Google Scholar 

  82. Rosenthal MA, Oratz R. Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma. Am J Clin Oncol. 1998; 212: 352–4

    Article  Google Scholar 

  83. Bunn PA, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med. 1994; 121: 592–602

    PubMed  Google Scholar 

  84. Kessler JF, Meyskens FL, Levine N, et al. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet. 1983; I (8338): 1345–7

    Article  Google Scholar 

  85. Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate: a study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1987; 67: 232–6

    PubMed  CAS  Google Scholar 

  86. Neely SM, Mehlmauer M, Feinstein DI. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma. Arch Intern Med. 1987; 147: 529–31

    Article  PubMed  CAS  Google Scholar 

  87. Burg G, Dummer R. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL). Clin Lymphoma. 2000; 1 Suppl. 1: S41–4

    PubMed  Google Scholar 

  88. Gupta AK, Chaudry MM. Critical review of the manner in which the efficacy of therapies for rosacea are evaluated. Int J Dermatol. 2003; 42: 909–16

    Article  PubMed  Google Scholar 

  89. Rebora A. The management of rosacea. Am J Clin Dermatol. 2002; 3: 489–96

    Article  PubMed  Google Scholar 

  90. Firooz A, Firoozabadi MR, Doelati Y. Rosacea fulminans (pyoderma faciale): successful treatment of a 3-year old girl with oral isotretinoin. Int J Dermatol. 2001; 40 (3): 203–5

    Article  PubMed  CAS  Google Scholar 

  91. Jansen T, Romiti R, Kreuter A, et al. Rosacea fulminans triggered by high-dose vitamins B6 and B12. J Fur Acad Dermatol Venereol. 2001; 15: 484–5

    Article  CAS  Google Scholar 

  92. Slade DEM, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg. 2003; 56: 451–61

    Article  PubMed  CAS  Google Scholar 

  93. Jansen T, Altmeyer P, Piewig G. Acne inversa (alias hidradenitis suppurativa). J Fur Acad Dermatol Venereol. 2001; 15: 532–40

    Article  CAS  Google Scholar 

  94. Brown CF, Gallup DG, Brown VM. Hidradenitis suppurativa of the anogenital region: response to isotretinoin. Am J Obstet Gynecol. 1988; 158: 12–5

    PubMed  CAS  Google Scholar 

  95. Schleicher SM, Milstein HJ. Resolution of disseminated granuloma annulare following isotretinoin therapy. Cutis. 1985; 36: 147–8

    PubMed  CAS  Google Scholar 

  96. Ratnavel RC, Norris PG. Perforating granuloma annulare: response to treatment with isotretinoin. J Am Acad Dermatol. 1995; 32: 126–7

    Article  PubMed  CAS  Google Scholar 

  97. Adams DC, Hogan DJ. Improvement of chronic generalized granuloma annulare with isotretinoin. Arch Dermatol. 2002; 138: 1518–9

    Article  PubMed  Google Scholar 

  98. Tang WYM, Chung LY, Lo K. Resolution of generalized granuloma annulare with isotretinoin therapy. Int J Dermatol. 1996; 35: 455–6

    Article  PubMed  CAS  Google Scholar 

  99. Erkek E, Karaduman A, Bdkülmez N, et al. An usual form of generalized granuloma annulare in a patient with insulin-dependent diabetes mellitus. Acta Derm Venerol. 2001; 81: 48–50

    Article  PubMed  CAS  Google Scholar 

  100. Green SG, Piette WW. Successful treatment of hypertrophic lupus erythematosus with isotretinoin. J Am Acad Dermatol. 1987; 17: 364–8

    Article  PubMed  CAS  Google Scholar 

  101. Furner BB. Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol. 1990; 29: 587–90

    Article  PubMed  CAS  Google Scholar 

  102. Shormick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol. 1991; 24: 49–52

    Article  Google Scholar 

  103. Richardson TT, Cohen PR. Subacute cutaneous lupus erythematosus: report of a patient who subsequently developed a meningioma and whose skin lesions were treated with isotretinoin. Cutis. 2000; 66: 183–8

    PubMed  CAS  Google Scholar 

  104. Handler HL. Isotretinoin for oral lichen planus [letter]. J Am Acad Dermatol. 1984; 10: 674

    Article  PubMed  CAS  Google Scholar 

  105. Woo TY. Systemic isotretinoin treatment of oral and cutaneous lichen planus. Cutis. 1985; 35: 385–6

    PubMed  CAS  Google Scholar 

  106. Camisa C, Allen CM. Treatment of oral erosive lichen planus with systemic isotretinoin. Oral Surg Oral Med Oral Pathol. 1986; 62: 393–6

    Article  PubMed  CAS  Google Scholar 

  107. Carlin CS, Florell SR, Krueger GG. Induction of dramatic hyperpigmentation in a patient with generalized lichen planus treated with re-PUVA. J Cutan Med Surg. 2002; 6: 125–7

    Article  PubMed  Google Scholar 

  108. Statham BN, Cunliffe WJ. The treatment of steatocystoma multiplex suppurativum with isotretinoin [letter]. Br J Dermatol. 1984; 111: 246

    Article  PubMed  CAS  Google Scholar 

  109. Schwartz JL, Goldsmith LA. Steatocystoma multiplex suppurativum: treatment with isotretinoin. Cutis. 1984; 34: 149–50

    PubMed  CAS  Google Scholar 

  110. Friedman SJ. Treatment of steatocystoma multiplex and pseudofolliculitis barbae with isotretinoin. Cutis. 1987; 39: 506–7

    PubMed  CAS  Google Scholar 

  111. Apaydin R, Bilen N, Bayramgurler D, et al. Steatocystoma multiplex suppurativum: oral isotretinoin treatment combined with cryotherapy. Australas J Dermatol. 2000; 41: 98–100

    Article  PubMed  CAS  Google Scholar 

  112. Hodge JA, Ray MC. Confluent and reticulated papillomatosis: response to isotretinoin [letter]. J Am Acad Dermatol. 1991; 24: 654

    Article  PubMed  CAS  Google Scholar 

  113. Lee MP, Stiller MJ, McClain SA, et al. Confluent and reticulated papillomatosis: response to high-dose oral isotretinoin therapy and reassessment of epidemiologic data. J Am Acad Dermatol. 1994; 31: 327–31

    Article  PubMed  Google Scholar 

  114. Solomon BA, Laude TA. Two patients with confluent and reticulated papillomatosis: response to oral isotretinoin and 10% lactic acid lotion. J Am Acad Dermatol. 1996; 35: 645–6

    Article  PubMed  CAS  Google Scholar 

  115. Spielvogel RL, DeVillez RL, Roberts LC. Oral isotretinoin therapy for familial Muir-Torre syndrome. J Am Acad Dermatol. 1985; 12: 475–80

    Article  PubMed  CAS  Google Scholar 

  116. Marcusson JA, Bjarnason B, Ros AM. Isotretinoin for sebaceous skin lesions in Muir-Torre syndrome: a case report. Acta Derm Venereol. 1998; 78: 479–80

    Article  PubMed  CAS  Google Scholar 

  117. Graefe T, Wollina U, Schulz H, et al. Muir-Torre syndrome: treatment with isotretinoin and interferon alpha-2a can prevent tumour development. Dermatology. 2000; 200: 331–3

    Article  PubMed  CAS  Google Scholar 

  118. Rubeiz N, Kibbi A-G. Management of ichthyosis in infants and children. Clin Dermatol. 2003; 21: 325–8

    Article  PubMed  Google Scholar 

  119. Baden HP, Buxman MM, Weinstein GD, et al. Treatment of ichthyosis with isotretinoin. J Am Acad Dermatol. 1982; 6 (4 Pt 2 Suppl.): 716–20

    Article  PubMed  CAS  Google Scholar 

  120. Venkataram M. Epidermolytic hyperkeratosis: failure of retinoid therapy. Retinoids. 2002; 18: 71–2

    Google Scholar 

  121. Milam CP, Cohen LE, Fenske NA, et al. Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol. 1988; 19: 469–77

    Article  PubMed  CAS  Google Scholar 

  122. Hisler BM, Savoy LB, Hashimoto K. Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol. 1991; 24: 854–7

    Article  PubMed  CAS  Google Scholar 

  123. Berbis P, Privat Y. Lupus miliaris disseminatus faciei: efficacy of isotretinoin. J Am Acad Dermatol. 1987; 16: 1271–2

    Article  PubMed  CAS  Google Scholar 

  124. Bahadir S, Apaydin R, Cimsit G, et al. Oral isotretinoin in two patients with lupus miliaris disseminatus faciei. J Dermatol Treat. 1999; 10: 205–8

    Article  Google Scholar 

  125. Omulecki A, Dabkowski J, Zak-Prelich M, et al. Perifolliculitis capitis abscedens et suffodiens — a case report. Med Sci Monit. 2000; 6: 602–4

    PubMed  CAS  Google Scholar 

  126. Scavo S, Dnazuso GL, La Rocca R, et al. Isotretinoin in perifollicultis capitis absceden et suffodiens: a case report and review of the literature. Clin Drug Invest. 2002; 22: 791–4

    Article  Google Scholar 

  127. Atom K, Aivaliotis M, Davaris P. Disseminated and recurrent infundibular folliculitis (D.R.I.F.): report of a case successfully treated with isotretinoin. J Dermalot. 1998; 25: 51–3

    Google Scholar 

  128. Çalka Ö, Metin A, Özen S. A case of disseminated and recurrent infundibulofol-liculitis responsive to treatment with systemic isotretinoin. J Dermatol. 2002; 29: 431–4

    PubMed  Google Scholar 

  129. Layton AM, Cunliffe WJ. A case of ulerythema ophryogenes responding to isotretinoin. Br J Dermatol. 1993; 129: 645–6

    Article  PubMed  CAS  Google Scholar 

  130. Gruss C, Zillikens D, Hashimoto T, et al. Rapid response of IgA pemphigus of subcomeal pustular dermatosis type to treatment with isotretinoin. J Am Acad Dermatol. 2000; 43: 923–6

    Article  PubMed  CAS  Google Scholar 

  131. Akyol M, Dogan S, Kaptanoglu E, et al. Systemic isotretinoin in the treatment of a Behcet’s patient with arthritic symptoms and acne lesions [letter]. Clin Exp Rheumatol. 2002; 20 (4 Suppl. 26): S–55

    PubMed  CAS  Google Scholar 

  132. Bachynsky T, Antonyshyn OM, Ross JB. Dissecting folliculitis of the scalp: a case report of combined treatment using tissue expansion, radical excision, and isotretinoin. J Dermatol Surg Oncol. 1992; 18: 877–80

    PubMed  CAS  Google Scholar 

  133. Weisshaar E, Schramm M, Gollnick H. Familial nevoid sebaceous gland hyperplasia affecting three generations of a family. Fur J Dermatol. 1999; 9: 621–3

    CAS  Google Scholar 

Download references

Acknowledgments

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Dermatology Department, School of Medicine of Cumhuriyet University, 58140, Sivas, Turkey

    Melih Akyol & Sedat Özçelik

Authors
  1. Melih Akyol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sedat Özçelik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melih Akyol.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akyol, M., Özçelik, S. Non-Acne Dermatologic Indications for Systemic Isotretinoin. Am J Clin Dermatol 6, 175–184 (2005). https://doi.org/10.2165/00128071-200506030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200506030-00004

Keywords

Search

Navigation